Clinical Trial Update: Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ofatumumab plus bendamustine hydrochloride, with or without bortezomib, in untreated follicular lymphoma; the study is completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Arzerra (ofatumumab)
• Treanda (Bendamustine)
• Velcade (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2019-01-10